Frost & Sullivan Research Evaluates Chantix As The Emerging Blockbuster Drug For Quit Smoking In US
Date: 17 th January 2008
A research on "US Smoking Cessation Market", undertaken by Frost & Sullivan identifies the quit smoking medicine chantix as the chartbuster medicine in the US pharmaceutical market and the Frost & Sullivan report concludes that chantix is expected to raise millions in sales and expand the pharmaceutical market.
Furthermore, with anti-smoking support programs such as GETQUIT included in chantix offers, the utilization of the medicine has increased tremendously and alongside other smoking cessation products are also increasingly used by smokers in order to get rid of smoking addiction.
It has also become apparent that the success shown by chantix in the US market has encouraged companies to manufacture treatment procedures capable of dealing with the psychological aspects of smoking.